ערך בספרים למניה: pasitheaclinics.com (KTTA)

Pasithea Therapeutics management combines clinical expertise and science to combat depression via the immune system. The book value per share on the GURU.Markets chart illustrates asset dynamics, where 1.50 captures the current value of the indicator. Steady confidence from the medical community is coupled with the logistics risks of rare compounds, which could slow down international trials.

Pasithea Therapeutics (KTTA) maintains a competitive advantage by attracting elite neurobiologists through a system of patent options, which directly impacts the capitalization of intellectual assets. An analysis of the book value per share demonstrates the residual value of equity after all liabilities are settled, allowing investors to assess the real financial stability of the business and the risk of equity impairment within the context of academic research.